AC Immune SA

NasdaqGM:ACIU

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

💉 Vaccines

Location

Switzerland

Market Cap

USD 184.10 M

Share Price

USD 1.83

Avg Daily Volume

154,409

Change (1 day)

-2.66%

Change (1 year)

-54.82%

Change (YTD)

-32.22%

AC Immune SA Share Price on June 23, 2025: USD 1.83

AC Immune SA Share Price is USD 1.83 on June 23, 2025, a -54.82% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

AC Immune SA 52-week low Share Price is USD 4.20 on June 23, 2025, which is 129.51% above the current Share Price.
AC Immune SA 52-week low Share Price is USD 1.48 on June 23, 2025, which is -19.13% below the current Share Price.
AC Immune SA average Share Price for the last 52 weeks is USD 2.76.

Daily

From:

To:

Zoom:

Key data

Date	Share Price	Share Price	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)

NasdaqGM: ACIU

AC Immune SA

CEO	Dr. Andrea Pfeifer Ph.D.
IPO Date	Sept. 23, 2016
Location	Switzerland
Headquarters	Building B
Employees	133
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals 💉 Vaccines

Description

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.